The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Abstract
A wealth of evidence has emerged that there is an association between aging, senescence and tumorigenesis. Senescence, a biological process by which cells cease to divide and enter a status of permanent cell cycle arrest, contributes to aging and aging-related diseases, including cancer. Aging populations have the higher incidence of cancer due to a lifetime of exposure to cancer-causing agents, reduction of repairing DNA damage, accumulated genetic mutations, and decreased immune system efficiency. Cancer patients undergoing cytotoxic therapies, such as chemotherapy and radiotherapy, accelerate aging. There is growing evidence that p53/MDM2 (murine double minute 2) axis is critically involved in regulation of aging, senescence and oncogenesis. Therefore, in this review, we describe the functions and mechanisms of p53/MDM2-mediated senescence, aging and carcinogenesis. Moreover, we highlight the small molecular inhibitors, natural compounds and PROTACs (proteolysis targeting chimeras) that target p53/MDM2 pathway to influence aging and cancer. Modification of p53/MDM2 could be a potential strategy for treatment of aging, senescence and tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The C-terminus of MDM2 is crucial for export of wild-type p53 from the nucleus to the cytoplasm, where it is degraded via E3 ubiquitin ligases.192,193”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [192]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Research works printed but not linked: 163
- Martin, 1996, Genetic analysis of ageing: role of oxidative damage and environmental stresses, Nat. Genet, 13, 25, 10.1038/ng0596-25 · DOI · Paper page
- Partridge, 2002, Mechanisms of ageing: public or private?, Nat. Rev. Genet, 3, 165, 10.1038/nrg753 · DOI · Paper page
- Melzer, 2020, The genetics of human ageing, Nat. Rev. Genet, 21, 88, 10.1038/s41576-019-0183-6 · DOI · Paper page
- Vitale, 2013, Oxidative stress and the ageing endocrine system, Nat. Rev. Endocrinol., 9, 228, 10.1038/nrendo.2013.29 · DOI · Paper page
- Benz, 2008, Ageing, oxidative stress and cancer: paradigms in parallax, Nat. Rev. Cancer, 8, 875, 10.1038/nrc2522 · DOI · Paper page
- Zhang, 2020, The ageing epigenome and its rejuvenation, Nat. Rev. Mol. Cell Biol., 21, 137, 10.1038/s41580-019-0204-5 · DOI · Paper page
- Ogrodnik, 2023, The meaning of adaptation in aging: insights from cellular senescence, epigenetic clocks and stem cell alterations, Nat. Aging, 3, 766, 10.1038/s43587-023-00447-5 · DOI
- Bitencourt, 2024, Subcellular structure, heterogeneity, and plasticity of senescent cells, Aging Cell, 10.1111/acel.14154 · DOI
- Pizzul, 2023, The multistep path to replicative senescence onset: zooming on triggering and inhibitory events at telomeric DNA, Front Cell Dev. Biol., 11, 10.3389/fcell.2023.1250264 · DOI
- Larsson, 2011, Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence, Semin Cancer Biol., 21, 367, 10.1016/j.semcancer.2011.10.005 · DOI
- Wang, 2022, Exploiting senescence for the treatment of cancer, Nat. Rev. Cancer, 22, 340, 10.1038/s41568-022-00450-9 · DOI · Paper page
- Guo, 2022, Aging and aging-related diseases: from molecular mechanisms to interventions and treatments, Signal Transduct. Target Ther., 7, 391, 10.1038/s41392-022-01251-0 · DOI · Paper page
- Lieber, 2004, Ageing, repetitive genomes and DNA damage, Nat. Rev. Mol. Cell Biol., 5, 69, 10.1038/nrm1281 · DOI
- Muss, 2020, p16 a biomarker of aging and tolerance for cancer therapy, Transl. Cancer Res, 9, 5732, 10.21037/tcr.2020.03.39 · DOI
- LaPak, 2014, The molecular balancing act of p16(INK4a) in cancer and aging, Mol. Cancer Res, 12, 167, 10.1158/1541-7786.MCR-13-0350 · DOI · Paper page
- Kennedy, 2014, RB and lamins in cell cycle regulation and aging, Adv. Exp. Med Biol., 773, 127, 10.1007/978-1-4899-8032-8_6 · DOI
- Fu, 2023, Targeting mTOR for anti-aging and anti-cancer therapy, Molecules, 28, 10.3390/molecules28073157 · DOI
- Ou, 2018, DNA damage responses and p53 in the aging process, Blood, 131, 488, 10.1182/blood-2017-07-746396 · DOI · Paper page
- Yi, 2010, SIRT1 and p53, effect on cancer, senescence and beyond, Biochim Biophys. Acta, 1804, 1684, 10.1016/j.bbapap.2010.05.002 · DOI · Paper page
- Wu, 2018, Relevance of the p53-MDM2 axis to aging, Cell Death Differ., 25, 169, 10.1038/cdd.2017.187 · DOI · Paper page
- Vazquez, 2008, The genetics of the p53 pathway, apoptosis and cancer therapy, Nat. Rev. Drug Discov., 7, 979, 10.1038/nrd2656 · DOI · Paper page
- Chang, 1995, Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein, J. Biol. Chem., 270, 25014, 10.1074/jbc.270.42.25014 · DOI
- Liu, 2003, The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein, J. Biol. Chem., 278, 17557, 10.1074/jbc.M210696200 · DOI
- Scoumanne, 2005, Structural basis for gene activation by p53 family members, Cancer Biol. Ther., 4, 1178, 10.4161/cbt.4.11.2254 · DOI
- Silva, 2013, Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor, Biosci. Rep., 33, 10.1042/BSR20130065 · DOI
- Dikic, 2023, An expanded lexicon for the ubiquitin code, Nat. Rev. Mol. Cell Biol., 24, 273, 10.1038/s41580-022-00543-1 · DOI · Paper page
- Popovic, 2014, Ubiquitination in disease pathogenesis and treatment, Nat. Med, 20, 1242, 10.1038/nm.3739 · DOI · Paper page
- Zheng, 2023, Elucidating the role of ubiquitination and deubiquitination in osteoarthritis progression, Front Immunol., 14, 1217466, 10.3389/fimmu.2023.1217466 · DOI
- Liu, 2022, Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy, Semin Cancer Biol., 86, 259, 10.1016/j.semcancer.2022.06.004 · DOI
- Wang, 2022, Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy, Semin Cancer Biol., 87, 84, 10.1016/j.semcancer.2022.11.002 · DOI
- Wang, 2014, Roles of F-box proteins in cancer, Nat. Rev. Cancer, 14, 233, 10.1038/nrc3700 · DOI · Paper page
- Senft, 2018, Ubiquitin ligases in oncogenic transformation and cancer therapy, Nat. Rev. Cancer, 18, 69, 10.1038/nrc.2017.105 · DOI · Paper page
- Dobbelstein, 2020, Mdm2: Open questions, Cancer Sci., 111, 2203, 10.1111/cas.14433 · DOI
- Tan, 2017, Anatomy of Mdm2 and Mdm4 in evolution, J. Mol. Cell Biol., 9, 3, 10.1093/jmcb/mjx002 · DOI · Paper page
- Lindstrom, 2007, Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions, Cell Cycle, 6, 434, 10.4161/cc.6.4.3861 · DOI
- Mendoza, 2014, The MDM2 gene family, Biomol. Concepts, 5, 9, 10.1515/bmc-2013-0027 · DOI
- O'Keefe, 2003, Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination, Mol. Cell Biol., 23, 6396, 10.1128/MCB.23.18.6396-6405.2003 · DOI
- Moqri, 2023, Biomarkers of aging for the identification and evaluation of longevity interventions, Cell, 186, 3758, 10.1016/j.cell.2023.08.003 · DOI · Paper page
- Zhavoronkov, 2019, Deep biomarkers of aging and longevity: from research to applications, Aging (Albany NY), 11, 10771, 10.18632/aging.102475 · DOI
- de Magalhaes, 2024, Distinguishing between driver and passenger mechanisms of aging, Nat. Genet, 56, 204, 10.1038/s41588-023-01627-0 · DOI
- Lin, 2024, MDMX in Cancer: A Partner of p53 and a p53-Independent Effector, Biologics, 18, 61
- Aguilar, 2022, Therapeutic strategies to activate p53, Pharm. (Basel), 16
- Dumble, 2004, Insights into aging obtained from p53 mutant mouse models, Ann. N. Y Acad. Sci., 1019, 171, 10.1196/annals.1297.027 · DOI
- Gentry, 2005, Complicating the role of p53 in aging, Aging Cell, 4, 157, 10.1111/j.1474-9726.2005.00154.x · DOI
- Garcia-Cao, 2002, Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally, EMBO J., 21, 6225, 10.1093/emboj/cdf595 · DOI · Paper page
- Liu, 2010, Puma is required for p53-induced depletion of adult stem cells, Nat. Cell Biol., 12, 993, 10.1038/ncb2100 · DOI
- Chao, 2006, Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression, EMBO J., 25, 2615
- Li, 2016, Loss of p53-mediated cell-cycle arrest, senescence and apoptosis promotes genomic instability and premature aging, Oncotarget, 7, 11838, 10.18632/oncotarget.7864 · DOI
- Maor-Nof, 2021, p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR), Cell, 184, 689, 10.1016/j.cell.2020.12.025 · DOI · Paper page
- Morganti, 2022, NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss, EMBO Rep., 23, 10.15252/embr.202154262 · DOI
- Lessel, 2017, Dysfunction of the MDM2/p53 axis is linked to premature aging, J. Clin. Invest, 127, 3598, 10.1172/JCI92171 · DOI
- Itahana, 2007, Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation, Cancer Cell, 12, 355, 10.1016/j.ccr.2007.09.007 · DOI · Paper page
- Pant, 2016, Distinct downstream targets manifest p53-dependent pathologies in mice, Oncogene, 35, 5713, 10.1038/onc.2016.111 · DOI
- Pant, 2013, The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity, Genes Dev., 27, 1857, 10.1101/gad.227249.113 · DOI
- Tollini, 2014, Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage, Cancer Cell, 26, 235, 10.1016/j.ccr.2014.06.006 · DOI
- Soussi, 2007, Shaping genetic alterations in human cancer: the p53 mutation paradigm, Cancer Cell, 12, 303, 10.1016/j.ccr.2007.10.001 · DOI · Paper page
- Figueiredo, 2006, Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation, J. Med Genet, 43, 91, 10.1136/jmg.2004.030551 · DOI · Paper page
- Attardi, 2005, Probing p53 biological functions through the use of genetically engineered mouse models, Mutat. Res, 576, 4, 10.1016/j.mrfmmm.2004.08.022 · DOI
- Lavigueur, 1989, High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene, Mol. Cell Biol., 9, 3982
- Lee, 1994, Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice, Oncogene, 9, 3731
- Harvey, 1995, A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice, Nat. Genet, 9, 305, 10.1038/ng0395-305 · DOI · Paper page
- Li, 1997, neu/ERBB2 cooperates with p53–172 H during mammary tumorigenesis in transgenic mice, Mol. Cell Biol., 17, 3155, 10.1128/MCB.17.6.3155 · DOI
- Klein, 2000, Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant, Oncogene, 19, 5329, 10.1038/sj.onc.1203941 · DOI
- Duan, 2002, Lung-specific expression of human mutant p53–273 H is associated with a high frequency of lung adenocarcinoma in transgenic mice, Oncogene, 21, 7831, 10.1038/sj.onc.1205909 · DOI
- Yin, 1998, Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutation in vivo, Hepatology, 27, 73, 10.1002/hep.510270113 · DOI
- Ghebranious, 1998, The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice, Hepatology, 27, 967, 10.1002/hep.510270411 · DOI
- Donehower, 1992, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature, 356, 215, 10.1038/356215a0 · DOI · Paper page
- Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
- Purdie, 1994, Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene, Oncogene, 9, 603
- Tsukada, 1993, Enhanced proliferative potential in culture of cells from p53-deficient mice, Oncogene, 8, 3313
- Armstrong, 1995, High-frequency developmental abnormalities in p53-deficient mice, Curr. Biol., 5, 931, 10.1016/S0960-9822(95)00183-7 · DOI · Paper page
- Sah, 1995, A subset of p53-deficient embryos exhibit exencephaly, Nat. Genet, 10, 175, 10.1038/ng0695-175 · DOI · Paper page
- Venkatachalam, 1998, Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation, EMBO J., 17, 4657, 10.1093/emboj/17.16.4657 · DOI · Paper page
- Venkatachalam, 2001, Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing, Toxicol. Pathol., 29, 147, 10.1080/019262301753178555 · DOI
- Harvey, 1993, Genetic background alters the spectrum of tumors that develop in p53-deficient mice, FASEB J., 7, 938, 10.1096/fasebj.7.10.8344491 · DOI · Paper page
- Kuperwasser, 2000, Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome, Am. J. Pathol., 157, 2151, 10.1016/S0002-9440(10)64853-5 · DOI · Paper page
- Jonkers, 2001, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer, Nat. Genet, 29, 418, 10.1038/ng747 · DOI · Paper page
- Xu, 2001, Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis, Nat. Genet, 28, 266, 10.1038/90108 · DOI · Paper page
- Xu, 1999, Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation, Nat. Genet, 22, 37, 10.1038/8743 · DOI · Paper page
- Blyth, 1995, Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss, Oncogene, 10, 1717
- Elson, 1995, The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice, Oncogene, 11, 181
- Curtis, 1997, The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice, Oncogene, 15, 2975, 10.1038/sj.onc.1201467 · doi:10.1038/sj.onc.1201467
- Brodie, 2001, Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis, Oncogene, 20, 1445, 10.1038/sj.onc.1204222 · DOI
- Donehower, 1995, Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability, Genes Dev., 9, 882, 10.1101/gad.9.7.882 · DOI · Paper page
- Hundley, 1997, Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53, Mol. Cell Biol., 17, 723, 10.1128/MCB.17.2.723 · DOI
- Marin, 1994, Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis, Oncogene, 9, 3107
- Harvey, 1995, Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin, Cancer Res, 55, 1146
- Williams, 1994, Cooperative tumorigenic effects of germline mutations in Rb and p53, Nat. Genet, 7, 480, 10.1038/ng0894-480 · DOI · Paper page
- Knudson, 2001, Bax accelerates tumorigenesis in p53-deficient mice, Cancer Res, 61, 659
- Hosokawa, 2001, In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53, Transgenic Res, 10, 471, 10.1023/A:1012064911751 · doi:10.1023/a:1012064911751
- Cichowski, 1999, Mouse models of tumor development in neurofibromatosis type 1, Science, 286, 2172, 10.1126/science.286.5447.2172 · DOI · Paper page
- Reilly, 2000, Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects, Nat. Genet, 26, 109, 10.1038/79075 · DOI · Paper page
- McClatchey, 1998, Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors, Genes Dev., 12, 1121, 10.1101/gad.12.8.1121 · DOI · Paper page
- Halberg, 2000, Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers, Proc. Natl. Acad. Sci. USA, 97, 3461, 10.1073/pnas.97.7.3461 · DOI
- Wetmore, 2001, Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched, Cancer Res, 61, 513
- Artandi, 2000, Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice, Nature, 406, 641, 10.1038/35020592 · DOI · Paper page
- Cornelissen, 2019, Exogenous ERalpha Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice, J. Mammary Gland Biol. Neoplasia, 24, 305, 10.1007/s10911-019-09437-z · DOI
- Reuss, 2023, Simultaneous Nbs1 and p53 inactivation in neural progenitors triggers high-grade gliomas, Neuropathol. Appl. Neurobiol., 49, 10.1111/nan.12915 · DOI
- Jones, 1998, Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis, Proc. Natl. Acad. Sci. USA, 95, 15608, 10.1073/pnas.95.26.15608 · DOI · Paper page
- Carr, 2016, Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis, Cell Rep., 16, 2618, 10.1016/j.celrep.2016.08.014 · DOI
- Macias, 2010, An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction, Cancer Cell, 18, 231, 10.1016/j.ccr.2010.08.007 · DOI · Paper page
- Meng, 2015, Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways, Oncogene, 34, 5709, 10.1038/onc.2015.39 · DOI
- Liu, 2017, Disruption of the RP-MDM2-p53 pathway accelerates APC loss-induced colorectal tumorigenesis, Oncogene, 36, 1374, 10.1038/onc.2016.301 · DOI
- Pan, 2011, The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression, PLoS One, 6, 10.1371/journal.pone.0021625 · DOI
- Cheng, 2010, Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis, Cancer Res, 70, 7684, 10.1158/0008-5472.CAN-09-3231 · DOI
- Han, 2022, PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective, Acta Mater. Med, 1, 244
- Bhatia, 2023, Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer, Curr. Med Chem., 30, 3668, 10.2174/0929867330666221114103924 · DOI
- Alaseem, 2023, Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens, Saudi Pharm. J., 31, 10.1016/j.jsps.2023.101790 · DOI
- Konopleva, 2020, MDM2 inhibition: an important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
- Rusiecki, 2019, MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present), Recent Pat. Anticancer Drug Discov., 14, 324, 10.2174/1574892814666191022163540 · DOI
- Cha, 2005, Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth, Cancer Res, 65, 2287, 10.1158/0008-5472.CAN-04-3250 · DOI · Paper page
- Rong, 2009, Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53, Cancer Lett., 284, 102, 10.1016/j.canlet.2009.04.011 · DOI
- Lai, 2012, Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo, PLoS One, 7, 10.1371/journal.pone.0042192 · DOI
- Jia, 2023, Ganoderic Acid A and Its Amide Derivatives as Potential Anti-Cancer Agents by Regulating the p53-MDM2 Pathway: Synthesis and Biological Evaluation, Molecules, 28, 10.3390/molecules28052374 · DOI
- Gao, 2020, Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells, Int J. Mol. Sci., 21, 10.3390/ijms21134642 · DOI
- Park, 2020, The Antiproliferative Activity of Oxypeucedanin via Induction of G(2)/M Phase Cell Cycle Arrest and p53-Dependent MDM2/p21 Expression in Human Hepatoma Cells, Molecules, 25
- Tin, 2014, Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells, BMC Biol., 12, 72, 10.1186/s12915-014-0072-6 · DOI
- Li, 2007, Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway, Cancer Res, 67, 1988, 10.1158/0008-5472.CAN-06-3066 · DOI · Paper page
- Gao, 2020, Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways, Aging (Albany NY), 12, 6240, 10.18632/aging.103019 · DOI
- Li, 2005, Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels, Cancer Res, 65, 8200, 10.1158/0008-5472.CAN-05-1302 · DOI
- Yu, 2020, Resveratrol promotes osteogenesis and alleviates osteoporosis by inhibiting p53, Aging (Albany NY), 12, 10359, 10.18632/aging.103262 · DOI
- Bekes, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
- Liu, 2022, Targeting micro-environmental pathways by PROTACs as a therapeutic strategy, Semin Cancer Biol., 86, 269, 10.1016/j.semcancer.2022.07.001 · DOI
- Kelm, 2023, PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy, Mol. Cancer, 22, 62, 10.1186/s12943-022-01707-5 · DOI
- Choudhary, 2023, Target protein degradation by protacs: A budding cancer treatment strategy, Pharm. Ther., 250, 10.1016/j.pharmthera.2023.108525 · DOI
- Inuzuka, 2022, PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives, Acta Mater. Med, 1, 24
- Wang, 2020, PhotoPROTACs: A Novel Biotechnology for Cancer Treatment, Trends Cell Biol., 30, 749, 10.1016/j.tcb.2020.08.003 · DOI
- Ahmad, 2023, Recent Advances in PROTAC-Based Antiviral Strategies, Vaccin. (Basel), 11
- He, 2024, Progress in the controllability technology of PROTAC, Eur. J. Med Chem., 265, 10.1016/j.ejmech.2023.116096 · DOI
- Chen, 2023, Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity, J. Med Chem., 66, 8428, 10.1021/acs.jmedchem.3c00302 · DOI
- Rovers, 2023, Methods for computer-assisted PROTAC design, Methods Enzym., 690, 311, 10.1016/bs.mie.2023.06.020 · DOI
- Wang, 2021, Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries, Eur. J. Med Chem., 219, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
- Wurz, 2019, Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors, J. Med Chem., 62, 445, 10.1021/acs.jmedchem.8b01945 · DOI
- Yang, 2023, Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2, J. Adv. Res, 45, 59, 10.1016/j.jare.2022.05.009 · DOI
- Adams, 2023, Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer, Cancer Discov., 13, 1210, 10.1158/2159-8290.CD-22-1131 · DOI
- Peuget, 2023, MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation, Cancer Discov., 13, 1043, 10.1158/2159-8290.CD-23-0229 · DOI
- Wang, 2023, Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer, Bioorg. Chem., 131, 10.1016/j.bioorg.2022.106327 · DOI
- Qi, 2021, Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein, Bioorg. Chem., 111, 10.1016/j.bioorg.2021.104901 · DOI · Paper page
- Marcellino, 2023, An MDM2 degrader for treatment of acute leukemias, Leukemia, 37, 370, 10.1038/s41375-022-01735-6 · DOI
- Chen, 2022, Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression, Theranostics, 12, 6665, 10.7150/thno.75444 · DOI
- Cui, 2023, Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide, Molecules, 28, 10.3390/molecules28093912 · DOI
- Dong, 2009, Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway, Mol. Cancer, 8, 103, 10.1186/1476-4598-8-103 · DOI · Paper page
- Kogan-Sakin, 2011, Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells, Cell Death Differ., 18, 271, 10.1038/cdd.2010.94 · DOI
- Kong, 2023, Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC, Clin. Transl. Med, 13, 10.1002/ctm2.1191 · DOI
- Chang, 2022, MDM2-BCL-X(L) PROTACs enable degradation of BCL-X(L) and stabilization of p53, Acta Mater. Med, 1, 333
- Armata, 2007, The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression, Cancer Res, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI
- Koyama, 2023, Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study, Cancer Discov., 13, 1814, 10.1158/2159-8290.CD-23-0419 · DOI
- Gounder, 2023, A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas, J. Clin. Oncol., 41, 1714, 10.1200/JCO.22.01285 · DOI
- LoRusso, 2023, The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study, Cancer Discov., 13, 1802, 10.1158/2159-8290.CD-23-0153 · DOI · Paper page
- Mascarenhas, 2022, The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study, Blood Adv., 6, 1162, 10.1182/bloodadvances.2021006043 · DOI
- Yan, 2021, A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity, Theranostics, 11, 6833, 10.7150/thno.59020 · DOI
- Billimoria, 2023, Senescence in cancer: Advances in detection and treatment modalities, Biochem Pharm., 215, 10.1016/j.bcp.2023.115739 · DOI
- Troiani, 2022, Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer, Nat. Commun., 13, 2177, 10.1038/s41467-022-29824-1 · DOI
- Eberhart, 2023, Killing zombies: Senolytic therapy in pilocytic astrocytoma, Neuro Oncol., 25, 748, 10.1093/neuonc/noad016 · DOI
- Carpenter, 2021, Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy, Biochem Pharm., 193, 10.1016/j.bcp.2021.114765 · DOI
- Sasaki, 2020, FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer, Cancers (Basel), 12, 10.3390/cancers12102976 · DOI
- Chang, 2024, Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation, Angew. Chem. Int Ed. Engl., 63, 10.1002/anie.202315425 · DOI
- Toufektchan, 2018, The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure, Cancers (Basel), 10, 10.3390/cancers10050135 · DOI
- Horikawa, 2011, p53 governs telomere regulation feedback too, via TRF2, Aging (Albany NY), 3, 26, 10.18632/aging.100271 · DOI
- Chou, 2022, Sirtuin-1 attenuates cadmium-induced renal cell senescence through p53 deacetylation, Ecotoxicol. Environ. Saf., 245, 10.1016/j.ecoenv.2022.114098 · DOI
- Yang, 2019, Sirtuin 2 expression suppresses oxidative stress and senescence of nucleus pulposus cells through inhibition of the p53/p21 pathway, Biochem Biophys. Res Commun., 513, 616, 10.1016/j.bbrc.2019.03.200 · DOI
- Solary, 2022, Ageing and cancer: a research gap to fill, Mol. Oncol., 16, 3220, 10.1002/1878-0261.13222 · DOI
- Carroll, 2022, Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care, Nat. Rev. Clin. Oncol., 19, 173, 10.1038/s41571-021-00580-3 · DOI
Cited by
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Huang, Y., Che, X., Wang, P. W., & Qu, X.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 101
- Pages
- 44-57
- ISSN
- 1044-579X
- Cited by
- 94
- References
- 43
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53/MDM2 signaling pathway in aging, senescence and tumorigenesis. https://app.cochat.ai/papers/10.1016/j.semcancer.2024.05.001
- The paper
- Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024). p53/MDM2 signaling pathway in aging, senescence and tumorigenesis. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2024.05.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.